---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-001065"
form_type: "8-K/A"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T05:28:16.964880+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Lyell closes ImmPACT Bio acquisition; acquired firm had $136.8M deficit, going concern flag

## Summary
- ImmPACT Bio's audited FY2023 net loss $58.9M, R&D spend $44.0M, accumulated deficit $136.8M.
- Auditors express substantial doubt about ImmPACT's ability to continue as a going concern due to recurring losses and negative cash flows.
- ImmPACT had $39.9M cash and equivalents, $1.2M short-term investments, $5.9M property/equipment as of Dec 31, 2023.
- Lyell completed acquisition of ImmPACT on Oct 31, 2024; combined pro forma financials filed for FY2023 and nine months ended Sep 30, 2024.

## SEC filing metadata
- accession: 0001628280-25-001065
- form_type: 8-K/A
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000162828025001065/0001628280-25-001065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000162828025001065/lyel-20241031.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-001065
- JSON: https://secwatch.observer/filing/0001628280-25-001065.json
- Plain text: https://secwatch.observer/filing/0001628280-25-001065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.